While the CFO's sale of 36% of his holdings could appear negative, it was part of a non-discretionary pre-arranged trading plan, not indicative of loss of confidence. The company's strong Q1 revenue growth (23.3M vs 1.3M YoY) and FDA orphan drug designation for Papzimeos are positive catalysts that offset insider selling concerns. The stock's 254.72% one-year return reflects market optimism.
Strong Q1 2026 results with PAPZIMEOS generating $21.6M in revenue, significant improvement in net loss ($7.9M vs $54.2M YoY), broad payer coverage (90%+ of insured lives), 400 patient hub enrollments, permanent J-code approval, and clear path to cash flow break-even by end of 2026. Positive momentum in commercial execution and pipeline advancement with PRGN-2009 in HPV-associated cancers.
Articles that tag PGEN but are mainly about other companies.
Mentioned as a better-ranked biotech stock with Zacks Rank #1, but no direct connection to the main article content about AbbVie's Juvmo approval.
Mentioned as a better-ranked biotech stock (Zacks Rank #1) with strong year-to-date performance and improving earnings estimates, but no direct news or developments related to this company in the article.
Zacks Rank #1 (Strong Buy) with improved earnings estimates; 2026 estimates improved from -2 cents to +24 cents EPS; 2027 estimates rose from 25 cents to 73 cents; stock up 86.9% YTD with consistent earnings beats.
Zacks Rank #1 (Strong Buy) with improved earnings estimates over past 60 days and strong year-to-date performance of +88.8%. Consistent earnings beats in trailing quarters.
Carries Zacks Rank #1 (Strong Buy) with improved earnings estimates over past 60 days and strong stock performance (+84% YTD). Consistent earnings beats with 108.96% average surprise.
Zacks Rank #1 (Strong Buy) rating with significantly improved earnings estimates (from losses to profitability) and strong year-to-date performance of +84.2%. Average earnings surprise of 108.96%.
Zacks Rank #1 (Strong Buy) with improving earnings estimates and strong year-to-date performance of +88.3%. Consistent earnings beats with average surprise of 108.96%.
Zacks Rank #1 (Strong Buy) with improved earnings estimates over past 60 days (2026 EPS improved from -$0.02 to $0.25; 2027 from $0.25 to $0.86). Consistent earnings beats in 3 of last 4 quarters with 108.96% average surprise. Stock up 63.7% year-to-date.
Mentioned as a better-ranked biotech stock (Zacks Rank #1) for comparison purposes only; no direct connection to the main article content.
Zacks Rank #1 (Strong Buy) with improving earnings estimates for 2026 and 2027, consistent earnings beats (3 of 4 quarters), and strong year-to-date share performance of +70.1%.
Zacks Rank #2 (Buy) with improved 2026 and 2027 earnings estimates over the past 60 days. Stock up 69.9% year to date with consistent earnings beats (3 of 4 quarters).
Carries Zacks Rank #1 (Strong Buy) with improved 2026-2027 earnings estimates and 68% year-to-date share price surge, demonstrating strong analyst confidence and market performance.
Zacks Rank #1 (Strong Buy) with improving earnings estimates (2026 loss of 2 cents improved to earnings of 25 cents), strong year-to-date performance (+65.8%), and consistent earnings beats (3 of 4 trailing quarters with 108.96% average surprise).
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
